Evidence map›Paper›PMID 41459744›Full record

ArticleNucleic acids research2025

A novel plasmid-based co-tethered transcription platform for high yield, high purity mRNA synthesis.

Purnima Mala, Ruptanu Banerjee, Amin Abek, James Forster Iii, Aniruddha Pinjari, Ashish A Kulkarni, Craig T Martin

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Purnima MalaDepartment of Chemistry, University of Massachusetts Amherst, 710 N Pleasant St, Amherst, MA 01003, United States.
Ruptanu BanerjeeDepartment of Chemistry, University of Massachusetts Amherst, 710 N Pleasant St, Amherst, MA 01003, United States.ORCID 0000-0002-5881-1549
Amin AbekDepartment of Chemistry, University of Massachusetts Amherst, 710 N Pleasant St, Amherst, MA 01003, United States.
James Forster IiiDepartment of Chemical Biomolecular Engineering, University of Massachusetts Amherst, 686 North Pleasant StreetAmherst, MA 01003, United States.
Aniruddha PinjariDepartment of Chemical Biomolecular Engineering, University of Massachusetts Amherst, 686 North Pleasant StreetAmherst, MA 01003, United States.
Ashish A KulkarniDepartment of Chemical Biomolecular Engineering, University of Massachusetts Amherst, 686 North Pleasant StreetAmherst, MA 01003, United States.
Craig T MartinDepartment of Chemistry, University of Massachusetts Amherst, 710 N Pleasant St, Amherst, MA 01003, United States.ORCID 0000-0003-1029-5239

Funding

Polymeric Nanomaterials for Probing and Modulating Innate Immune ResponsesR35GM147019 · NIGMS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI Ashish A. Kulkarni · 2022 to 2026
$2.0M
MFB: Fluidics system for efficient site-specific labeling of RNAsR01HG013861 · NHGRI · UNIVERSITY OF MASSACHUSETTS AMHERST · PI Craig T Martin · 2024 to 2026
$1.3M
Systems for Dramatically Improved Synthetic RNAR01GM134042 · NIGMS · UNIVERSITY OF MASSACHUSETTS AMHERST · PI MARTIN, CRAIG T · 2020 to 2023
$1.2M
National Research Service Award T32GM135096NHGRI NIH HHS R01 HG013861NIGMS NIH HHS R01 GM134042NIH HHS 1R01GM134042NIH HHS R01HG013861NIH HHS R35GM147019University of MassachusettsWellcome Leap
6 · The paper itself

Abstract

This work aims to improve RNA synthesis and manufacturing, exemplified by T7 RNA polymerase-driven in vitro transcription. We developed a novel, plasmid-compatible co-tethering strategy that functionally couples RNA polymerase to its promoter DNA immobilized on a solid matrix. As demonstrated recently, co-tethering enhances promoter binding, increases RNA yield, and suppresses RNA re-binding, especially under high-salt conditions, thereby reducing double-stranded RNA by-products. The system leverages asymmetric end-labeling of linearized plasmid DNA using a simple "Klenow fill-in" reaction with modified nucleotides, enabling stable attachment of DNA to both RNA polymerase and solid support (magnetic beads). The immobilized co-tethered polymerase-DNA complex supports efficient transcription initiation in high-salt environments (which further reduces RNA re-binding), yielding RNA of high purity. Co-tethered complex remains functionally stable over extended storage and multiple transcription cycles (10-20 rounds), re-using the enzyme-DNA catalyst. Transcripts of lengths (0.8, 5.6, and 8.6 kb) are efficiently produced. Highly sensitive in vitro assays with immune cells confirm low immunogenicity and strong translational output, while in vivo validation using a novel Matrigel-plugged mouse model demonstrates robust expression and safety. With a simple modification to the DNA template, the reusable, co-tethered enzyme-DNA catalytic complex streamlines mRNA manufacturing by producing RNA of higher purity from the outset.

Indexed as

DNA-Directed RNA PolymerasesPlasmidsRNA, MessengerTranscription, GeneticViral ProteinsAnimalsDNAHumansMicePromoter Regions, Geneticbacteriophage T7 RNA polymeraseDNADNA-Directed RNA PolymerasesRNA, MessengerViral Proteins

Identifiers

PMID41459744
PMCPMC12746099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.